JeNaCell Releases Wound Dressing epicite balance

Evonik company JeNaCell has launched the wound dressing epicite balance to the German market.

The dressing is particularly suited and optimized for treating chronic wounds with low to medium exudation, such as venous leg ulcers, arterial leg ulcers, diabetic foot ulcers, pressure ulcers and soft tissue lesions. epicite balance is made in three different sizes and will be distributed through the company Coopmed ApS to hospitals and homecare centers. 
 
“epicite balance offers new treatment options for chronic wounds. The isotonic saline solution creates a moist wound environment, while the biosynthetic cellulose matrix can absorb wound exudate,” said Dr. Dana Kralisch, general manager of JeNaCell and co-developer of epicite balance. “Chronic wounds are often called the silent epidemic. They are affecting up to two percent of the population in industrialized countries, especially elderly patients.”
 
epicite balance is made of biosynthetic cellulose, a hydropolymer for medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds. epicite balance is manufactured in Germany by JeNaCell through a proprietary fermentation process using renewable carbon sources. 
 
This wound dressing is the latest addition to JeNaCell’s portfolio. The company develops and produces biosynthetic cellulose for medical device applications, implants, and drug delivery. JeNaCell was originally founded in 2012 as a spin-off of the Friedrich Schiller University Jena in Germany. In 2017, the firm debuted its first product—epicite hydro—a wound dressing for treating burns. Evonik acquired JeNaCell in 2021 after a prior a venture capital investment.
 
Evonik’s Health Care business line is a global system solutions provider for life science markets. 

Evonik is a world leader in specialty chemicals. The company is active in more than 100 countries and generated €18.5 billion in sales and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. The firm employs about 34,000 workers.